BB Biotech AG Overview
Pro stress-test →BB Biotech invests in biotechnology companies developing breakthrough drugs addressing significant unmet medical needs, and has stood for long-term, conviction-driven investment in innovative biotechnology companies for more than 30 years. It is one of the largest investment companies in the biotech sector.
Strategic Profile
Pro stress-test →Primary focus lies on small-to-mid-cap biotech companies headquartered in Western Europe and especially the United States market. BB Biotech targets a concentrated portfolio of 20–35 of the most promising biotech companies, with about two-thirds held in five to eight larger stocks that already have products on the market and the remaining third in stocks with promising drug candidates in advanced stages of development.
Competitive Landscape
Pro stress-test →BB Biotech is one of the largest investment companies in the biotech sector. It competes with other biotech-focused closed-end funds and open-ended mutual funds specializing in biotechnology. Key competitive advantages include long-term capital structure, deep scientific expertise through Bellevue Asset Management, and concentrated portfolio approach focusing on commercial-stage companies.
Industry Context
BB Biotech AG operates in Biotechnology Investment / Closed-End Fund Management.
Key facts
Founded: 1993 · Headquarters: Schaffhausen, Switzerland · Employees: N/A (externally managed by Bellevue Asset Management) · Revenue: Not applicable (investment company) · Market cap: CHF 2.50B